FIGHT-202 anti-FGFR2 pemigatinib for FGFR2 fusion cholangiocarcinoma. Very impressive
3-arm non-randomized phase 2
Primary endpoint ORR in cohort A FGFR2 fusion cohort
Incidence of FGFR2 fusion:
35% ORR
PFS
OS
Enough for accelerated conditional approval???
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.